BLCO Bausch + Lomb Corp: Enterprise Value to EBITDA Ratio

bausch.com - graphic logo of issuer BLCO

Stable solution sales support the resilience of Bausch + Lomb Corporation (BLCO), and on GURU.Markets, the historical EV/EBITDA value is captured via 13.36, reflecting the metric's latest value. The foundation of success is based on customer habits regarding eye care, which creates a powerful revenue stream. The defensive profile of the assets guarantees demand even during recessions, eliminating the impact of seasonality.

Bausch + Lomb Corp - BLCO Company Value to EBITDA (period 11/23/2025 - 11/16/2026)

Bausch + Lomb (BLCO) - metric breakdowns and financial figures

- current price and projected stock value:
Fundamental company analysis:Bausch Health (BLCO)
Product sample of bausch.com

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the real value of assets without the influence of tax policy. By analyzing the EV/EBITDA valuation trend, an investor can track how the successful launch of Miebo and premium optics reduces the debt load of Bausch + Lomb Corporation (BLCO), transforming operational successes into increased capitalization.

Competitors of Bausch + Lomb Corporation

Alcon Inc - Enterprise Value to EBITDA Ratio|Glaukos (GKOS) - Company Value to EBITDA|APLS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Belite Bio Corp|OCUL: EV/EBITDA Multiple|Company Value to EBITDA Harrow Corp (HROW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization viridiantherapeutics.com|lenz-tx.com (LENZ) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OCS|EYPT - Company Value to EBITDA|EV/EBITDA Multiple KOD (Kodiak Sciences Inc.)|Aldeyra - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KALA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Opus Genetics, Inc. IRD|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Adverum (ADVM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization outlooktherapeutics.com|CLSD: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio NBY (NovaBay Pharmaceuticals)|KPRX (Kiora Pharmaceuticals Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALIM (Alimera Sciences Inc)|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Corp (EYEN)|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Ocuphire Pharma, Inc.|opthea.com (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization